Clinical Effect of Tislelizumab Combined with Chemotherapy in the Treatment of Stage IIIb–IV Non-Small Cell Lung Cancer

Jie Jiang
{"title":"Clinical Effect of Tislelizumab Combined with Chemotherapy in the Treatment of Stage IIIb–IV Non-Small Cell Lung Cancer","authors":"Jie Jiang","doi":"10.26689/par.v8i4.7901","DOIUrl":null,"url":null,"abstract":"Objective: To analyze the therapeutic effect of tislelizumab combined with chemotherapy in patients with stage IIIb–IV non-small cell lung cancer (NSCLC). Methods: A total of 50 patients with stage IIIb–IV NSCLC admitted between January 2022 and January 2024 were randomly divided into two groups using a random number table. The observation group included 25 cases treated with tislelizumab combined with chemotherapy, while the reference group included 25 cases treated with conventional chemotherapy. The clinical control rate, adverse reaction rate, tumor markers, immune function indicators, and quality of life scores were compared between the two groups. Results: The observation group had a higher clinical control rate and a lower adverse reaction rate compared to the reference group (P < 0.05). Before treatment, there were no significant differences in tumor markers, immune function indicators, and quality of life scores between the two groups (P > 0.05). Three months after treatment, the tumor marker levels in the observation group were lower than those in the reference group. Except for CD8+, all immune function indicators in the observation group were higher than those in the reference group, and the quality-of-life scores in the observation group were higher than those in the reference group (P < 0.05). Conclusion: Implementing tislelizumab combined with chemotherapy in patients with stage IIIb–IV NSCLC can improve the clinical control rate, reduce the adverse reaction rate, lower tumor marker levels, protect immune function, and improve quality of life.","PeriodicalId":20511,"journal":{"name":"Proceedings of Anticancer Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of Anticancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26689/par.v8i4.7901","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To analyze the therapeutic effect of tislelizumab combined with chemotherapy in patients with stage IIIb–IV non-small cell lung cancer (NSCLC). Methods: A total of 50 patients with stage IIIb–IV NSCLC admitted between January 2022 and January 2024 were randomly divided into two groups using a random number table. The observation group included 25 cases treated with tislelizumab combined with chemotherapy, while the reference group included 25 cases treated with conventional chemotherapy. The clinical control rate, adverse reaction rate, tumor markers, immune function indicators, and quality of life scores were compared between the two groups. Results: The observation group had a higher clinical control rate and a lower adverse reaction rate compared to the reference group (P < 0.05). Before treatment, there were no significant differences in tumor markers, immune function indicators, and quality of life scores between the two groups (P > 0.05). Three months after treatment, the tumor marker levels in the observation group were lower than those in the reference group. Except for CD8+, all immune function indicators in the observation group were higher than those in the reference group, and the quality-of-life scores in the observation group were higher than those in the reference group (P < 0.05). Conclusion: Implementing tislelizumab combined with chemotherapy in patients with stage IIIb–IV NSCLC can improve the clinical control rate, reduce the adverse reaction rate, lower tumor marker levels, protect immune function, and improve quality of life.
Tislelizumab 联合化疗治疗 IIIb-IV 期非小细胞肺癌的临床效果
目的分析替斯利珠单抗联合化疗对 IIIb-IV 期非小细胞肺癌(NSCLC)患者的治疗效果。研究方法采用随机数字表法将2022年1月至2024年1月期间收治的50例IIIb-IV期NSCLC患者随机分为两组。观察组包括25例接受替斯利珠单抗联合化疗的患者,参照组包括25例接受常规化疗的患者。比较两组的临床控制率、不良反应率、肿瘤标志物、免疫功能指标和生活质量评分。结果显示与参照组相比,观察组的临床控制率更高,不良反应率更低(P < 0.05)。治疗前,两组的肿瘤标志物、免疫功能指标和生活质量评分无明显差异(P > 0.05)。治疗三个月后,观察组的肿瘤标志物水平低于参照组。除 CD8+ 外,观察组的所有免疫功能指标均高于参照组,观察组的生活质量评分高于参照组(P < 0.05)。结论对IIIb-IV期NSCLC患者实施替斯利珠单抗联合化疗可提高临床控制率,降低不良反应率,降低肿瘤标志物水平,保护免疫功能,改善生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信